Quantitative competitive PCR was used to monitor the quantity of cytomegalovirus (HCMV) in 1647 blood samples from 110 BMT recipients. DNAemia was detected in 49/110 (45%) of the patients, of whom 15/49 experienced HCMV disease. Peak virus load during surveillance was elevated in symptomatic (median 4.5 log 10 genomes/ml) vs asymptomatic patients (median 3.6 log 10 genomes/ml, P = 0.002) and was also significantly elevated in HCMV seropositive recipients of seronegative marrow, (R+D−, median 5.0 log 10 ), compared to those in the R−D− and R+D+ groups (P Ͻ 0.01 and Ͻ0.005). Odds ratios for disease per 0.25 log 10 increase in viral load, recipient seropositivity and aGVHD were 1.43 (P = 0.004), 6.60 (P = 0.05) and 3.17 (P = 0.08), respectively. In multivariate logistic regression analysis only elevated viral load remained a significant risk factor for HCMV disease. The computed disease probability viral load curve showed a rapid increase in disease risk at viral loads between 3.8 and 5.5 log 10 genomes/ml in blood, and odds ratios for disease were determined for different threshold viral loads. These data demonstrate the central role of viral load in the pathogenesis of HCMV in BMT recipients and provide an additional marker for targeting and monitoring therapy.
merase chain reaction (PCR) [9] [10] [11] have illustrated the frequency with which HCMV reactivates post-transplant and have identified the clinical utility of monitoring patients prospectively. These assays have allowed patient management strategies to be developed so that pre-emptive therapy is now widely used. 12, 13 In addition, placebo-controlled trials of ganciclovir (GCV) and acyclovir (ACV), have demonstrated that these drugs can decrease HCMV infection and, in some cases, disease when used prophylactically. [14] [15] [16] [17] Nevertheless, HCMV continues to cause significant disease in bone marrow recipients, necessitating continued routine surveillance for HCMV coupled with specific diagnostic testing in target organs such as lung, liver and gut. Despite the significant reduction in HCMV disease during the first 100 days post-transplant offered by prophylactic GCV strategies there is an increasing appreciation that late presentation of HCMV disease can occur (Ͼ100 days post-transplant) which has a high mortality. 18 In other patient populations at risk of HCMV disease, quantification of HCMV load has provided another risk factor for HCMV disease. Specifically, cross-sectional and longitudinal studies have indicated the importance of monitoring HCMV load in congenitally infected infants, 19 renal transplant recipients [20] [21] [22] and HIV infected patients. 23, 24 There is, however, a paucity of information on longitudinal fluctuations in cytomegalovirus load in the bone marrow transplant patient. 25 Previous studies in our laboratory have used a quantitative-competitive PCR assay for HCMV to show that HCMV load in the urine of renal transplant recipients and in the blood of liver-transplant patients is a significant risk factor for HCMV disease independent of other risk factors. 20, 21 We were interested to ascertain whether a similar situation exists in the bone marrow transplant patient group and if the previously reported risk factors for disease of recipient seropositivity and acute graft-versus-host disease 26, 27 were accounted for by increased viral load.
Patients and methods

Patients
Patients requiring bone marrow transplantation for a variety of conditions including leukaemias, solid organ tumours and aplastic anaemia were monitored for HCMV in the blood by PCR prior to transplantation and then at approxi-mately weekly intervals post-transplant. Recipients of autologous marrow and allografts were subjected to the same weekly surveillance. Where clinically indicated, other samples were assessed for cytomegalovirus infection by conventional cell culture, detection of immediate-early antigen fluorescent foci (DEAFF), and histopathology. During the period between June 1992 and September 1995, 110 bone marrow transplant recipients were monitored in real time for the presence of HCMV in the blood by qualitative PCR (qPCR) and any positive samples were subsequently subjected to quantitative-competitive PCR (QCPCR). All QCPCR assays were performed in a blinded fashion. Seventy-four of 110 (67%) patients received allografts from either a relative or an HLA-matched volunteer, and 36/110 (33%) received autografts from marrow harvested during remission and before conditioning treatment prior to transplantation. Of sibling donated allografts, 73% were T celldepleted, and 93% of allografts from matched unrelated donors (MUD) were T cell-depleted (depletion range 40-98%). Allograft recipients were given GVHD prophylaxis with cyclosporin A. Autografts were not T cell-depleted. The age of the patients ranged between 6 and 42 years. Donor and recipient serostatus for HCMV was analysed using a specific RIA as previously described. 28 Details of antiviral chemotherapy and other interventions, as well as clinical symptoms and laboratory results for haematological profiles during the post-transplant period were obtained from the patient's clinical notes.
Definitions of HCMV disease
Patients were classified as symptomatic if they had one or more of the symptoms defined by the International Workshop on HCMV Disease. 29 Case definitions were as follows: Pneumonia: Clinical symptoms of pneumoniaradiographic and/or hypoxemia plus HCMV in bronchoalveolar lavage (BAL) or lung biopsy. Gastrointestinal disease: Gastrointestinal symptoms plus histological evidence of HCMV from gut biopsies. Hepatitis: A combination of abnormal liver function tests (minimum of twice the upper level of normal for 2 consecutive days) and histopathological changes consistent with viral hepatitis together with HCMV in liver biopsy by culture, immunohistochemistry, in situ hybridization or PCR. Neurological disease: symptoms of encephalitis, transverse myelitis or other signs of diffuse CNS disease together with detection of CMV in CSF by PCR, culture or DEAFF. Retinitis: Typical retinal lesions diagnosed by an experienced ophthalmologist.
Qualitative PCR (qPCR)
Amplification of a 149 bp target sequence from the glycoprotein B region of the HCMV genome was used to identify HCMV infection in blood. 30 DNA was extracted from 200 l of whole blood (in preservative-free heparin) using commercially available ion exchange columns. (Qiagen, Digene, Germany). Blood DNA extracts (5 l) were analysed at both neat and at a 1/20 dilution to reduce the possibility of inhibitory effects from input material. PCR amplification was carried out in a 100-l reaction volume with 200 m dNTPs (Promega, Southampton, UK), 120 ng each of primers gB1 (5′-GAGGACAACGAAATCCTGTTGG-GCA) and gB2 (5′-GTCGACGGTGGAGATACTGCTG-AGG), 2 mm MgCl 2 , and 16.67 mM NH 4 SO 2 buffer pH 7.6, and 0.2 units of Taq polymerase (Perkin Elmer, Bucks, UK). Thermal cycling conditions were as follows: 94°C for 4 min, followed by 40 cycles of 94°C for 30 s, 60°C for 30 s and 72°C for 30 s. 20 l of amplified product was analysed by electrophoresis through a 3% agarose gel with appropriate size markers. All HCMV-positive results were confirmed by repeating the PCR reaction on the original clinical sample. The qualitative PCR has been optimised to reproducibly detect 200 genome copies per ml (ge/ml) of blood. The veracity of the HCMV amplicons has previously been established. 31 
Quantitative competitive PCR (QCPCR)
Blood samples that contained HCMV by qPCR were subsequently analysed by QCPCR as previously described. 32 Briefly, 5 l of DNA extract was co-amplified together with a known copy number (between 50 and 10 000 copies), of control DNA (a 149 bp CMVsequence from AD169, which had been mutated to produce a unique restriction site for Hpa1
32
). Reaction conditions were as described for the qPCR, except for the addition of 3 ng of 5′-32 P-labelled gB2 primer (100 kBq). Following amplification, 10 l of the amplified product was digested overnight with 3 units of Hpa1 at 37°C and the digestion products resolved on a 12% polyacrylamide gel. The gel was stained with ethidium bromide, photographed to confirm complete digestion of amplicons derived from the control sequence, and then exposed to radiography film (Hyperfilm MP; Amersham, UK). DNA fragments corresponding to digested (77 bp) control DNA and undigested (149 bp) target HCMV DNA were quantitated by scanning densitometry to obtain a target:control ratio from which the HCMV genome copy number per ml of blood was calculated. The QCPCR was similarly optimised to detect 200 genome copies of viral DNA per ml of whole blood.
Antiviral chemotherapy
Acyclovir, 10 mg/kg three times daily during in-patient stay and 800 mg four times daily p.o. subsequently for 150 days post-transplant was administered prophylactically to all allograft recipients. Ganciclovir (induction dose: 5 mg/kg 12 hourly, maintenance therapy at 6 mg/kg daily dosage dependent on the patient's creatinine clearance) or foscarnet (60 mg/kg three times daily) was given where clinically indicated, ie for symptoms of hypoxia, interstitial shadowing or persistent fever not resolved by antibiotics and antifungals, or the presence of HCMV by the DEAFF test in bronchoalveolar lavage fluid (BAL). Since November 1994, GCV therapy could be initiated on the basis of two consecutive PCR positive results in blood. When administration of ganciclovir or foscarnet was contraindicated highdose acyclovir (800 mg, five times a day) was used.
Statistical methods
The significance of differences between maximum viral loads in groups was assessed by the Mann-Whitney test. Initially, univariate relationships between the development of HCMV disease and the factors of interest were studied using Fisher's exact test or 2 test with continuity adjustment as appropriate (recipient serostatus) or Mann-Whitney U test (differences in viral load). Where significant, these relationships were then quantified using logistic regression (both univariate and multivariate), and the results used to generate an equation to determine the expected probability of being symptomatic at any given viral load. For these analyses, odds ratios quoted refer to a 0.25 log 10 increase in viral load.
Results
One hundred and ten bone marrow transplant recipients were monitored for the presence of HCMV infection in the blood post-transplant by qualitative PCR. DNAemia was detected in 49 patients (45%). All PCR positive samples were then subjected to quantification using a quantitative competitive PCR assay. A summary of type of transplant, donor/recipient serostatus for HCMV, peak virus load, and symptomatology for patients who were PCR positive for HCMV in blood is shown in Table 1 . Overall, 15 patients experienced HCMV disease that reached the internationally agreed criteria outlined in Patients and methods. As expected, HCMV disease was seen more frequently in allogeneic marrow recipients (14/74) than in autologous transplant patients (1/36; P = 0.03). Individual longitudinal viral load profiles for a selection of patients are shown in Figure 1 . The viral load profiles differed markedly between symptomatic (Figure 1b ) and asymptomatic individuals (Figure 1a ) with asymptomatic patients often exhibiting low viral loads which were only detected transiently. In contrast, symptomatic patients possessed higher viral loads which remained elevated for substantial periods of time. In some instances, for example patient 11, elevated virus load during surveillance correlated with onset of overt clinical symptoms. However, in the case of HCMV pneumonitis the peak virus load frequently preceded the onset of disease (eg patients 12 and 13). In the 10 patients with pneumonitis, peak virus load preceded clinically apparent disease by a median of 57 days (range −279 to +73 days).
In symptomatic patients the first blood PCR-positive result preceded diagnosis of CMV disease by a median of 70 days. In symptomatic patients the first PCR-positive result was obtained at a median of 25 days post-transplant, in asymptomatic patients at 28 days post-transplant. In patients who were HCMV PCR-positive post-transplant, we analysed the time to detection of HCMV DNAemia, peak virus load and disease in recipients of allograft vs autografts, and recipients of sibling-donated marrow or matched unrelated marrow. There was no significant difference between the time to detection of HCMV DNA and graft type (P = 0.28), nor was there a difference between peak virus load and type of graft (P = 0.26). Patients who received autografts had a lower peak virus load than allograft recipients (P = 0.04, Mann-Whitney U test). Three of nine recipients of MUD marrow developed disease, compared with 11/28 recipients of sibling donated marrow (P = 0.52). In contrast, 1/12 recipients of autografts who had CMV viraemia developed disease, compared with 14/34 allograft recipients (P = 0.05).
The relationship between peak virus load and disease is shown in Figure 2 . Viral load was significantly elevated in symptomatic patients (median 4.5 log 10 ge/ml blood; range 3.6-6.0) compared to asymptomatic patients (median 3.8 log 10 ge/ml blood; range 2.7-5.6) (P = 0.002). Since the number of surveillance samples obtained from asymptomatic and symptomatic patients were similar (median 23 per 
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CMV ge/ml log10 (blood) Figure 1 Continued patient, range 1-46 for both groups, autografts and allografts), we investigated the relationship between peak virus load during surveillance and number of surveillance samples positive for HCMV by PCR. These results are shown in Figure 3 and indicate that high viral loads correlated with a higher frequency of positive surveillance samples, ie a greater overall viral load as defined by the total area under the viral load time curve (AUC). The risks for disease associated with specific HCMV recipient-donor combinations in the study population on whom viral loads were measured are summarised in Table 2 . Compared to the R−D− group, disease was most common in patients who were seropositive recipients of seronegative donor marrow, with an odds ratio of 6.6. Comparable odds ratios were obtained when all 110 patients were subjected to similar analyses (data not shown). We subsequently investigated the relationship between peak viral load and donor/recipient serostatus for HCMV at the time of transplant. The results shown in Figure 4 and Table 2 illustrate that seropositive recipients of a seronegative marrow had a higher median viral load (5.0 log 10 ge/ml, range 2.7-6.0) than all other recipient-donor combinations (R+D− vs all other combinations; P = 0.007). Analysis of viral load differences between individual groups showed that the viral loads in the R+D− group were significantly higher than viral loads in either the R−D− or R+D+ groups but the difference between the R+D− and R−D+ did not reach statistical significance due to the small number of patients in the R−D+ group.
In PCR-positive patients, the odds ratios for disease associated with elevated viral load, reactivation of recipient cytomegalovirus strains, and the presence of acute GVHD were analysed using a logistic regression model. The results of the univariate analysis are summarised in Table 3 and show that elevated virus load and receipt of a seronegative marrow by a seropositive recipient was significantly associated with risk of CMV disease (odds ratio 1.43 per 0.25 log 10 increase in virus load, P = 0.05). There was also a trend (P = 0.08) towards an increased risk of disease with aGVHD. There was, however, no difference in the median maximal viral loads in patients with or without aGVHD (median loads 3.90 and 3.95 respectively, see Figure 5 ). In multivariate analysis, virus load remained a significant risk factor for disease (P = 0.006) after controlling for aGVHD and recipient serostatus whereas the association of both aGVHD and R+D− serostatus were negated once the effect of virus load was controlled for (P = 0.11 and 0.93, respectively).
The logistic regression model was used to produce an equation describing the probability of HCMV disease with increasing viral load. A fitted viral load disease probability curve was produced using this data (Figure 6 ), and the sensitivities and specificities of the model, together with the negative and positive predictive values are shown in HCMV ge/ml log10 (blood) Figure 2 The relationship between peak virus load and HCMV disease. Virus load was significantly elevated (P = 0.0001) in patients with symptomatic infection. No. PCR-positive samples/patient Peak virus load log10 ge/ml (blood) P = 0.0001 Rho = 0.74 Figure 3 Correlation between the number of PCR-positive samples during the surveillance period for each patient and peak virus load. , indicates multiple patients with the same peak virus load and number of PCRpositive samples.
Table 2
The relationship between recipient/donor serostatus for HCMV and odds ratio for HCMV disease in PCR-positive patients
Donor recipient
Odds ratio 95% C.I. Table 4 . Odds ratios for HCMV disease were calculated at virus load levels of 4.0 and 5.0 log 10 ge/ml in blood as 6.4 (95% confidence interval, 1.5-27.4) and 10.66 (95% CI, 1.8-60.5), respectively. Thus, at a peak blood viral load of 4.0 log 10 ge/ml there was a 6.46-fold increased probability of disease, which increased to over 10-fold at a peak virus load of 5.0 log 10 ge/ml. Since the majority of the patients in this study were treated with GCV on clinical grounds rather than on the basis of PCR positivity, we were interested to compare peak virus load between patients who received GCV therapy and those who did not. The results shown in Figure 7 illustrate that GCV-treated patients had a 1.0 log 10 higher peak virus load than untreated patients (P = 0.0002).
P value serostatus for HCMV
R−D− 1 - -
Discussion
In this study we have used quantitative PCR analysis to monitor fluctuations in cytomegalovirus load following bone marrow transplantation and to relate viral loads with symptomatology and previously recognised risk factors for HCMV disease. The results demonstrate the central role of elevated viral load in the pathogenesis of HCMV in this patient group. Thus, the median peak viral load in symptomatic patients was 0.7 log 10 higher than the viral load in patients who remained asymptomatic (P Ͻ 0.002) and was Values calculated for each viral load threshold relative to the total number of patients with disease rather than patients present within the viral load strata.
significantly elevated in HCMV-seropositive recipients of seronegative donor marrow (P = 0.007). Consistent with previous studies this sub-group of patients was most at risk of HCMV disease. 33 The higher risk of disease in this group is consistent with other reports associating T cell depletion with an increased risk of CMV pneumonia. 34 In contrast, peak viral loads between the remaining recipient-donor combinations were comparable (approximately 3.7 log 10 ge/ml) including patients acquiring primary infection from exogenous sources (R−D−). It should be noted that seronegative patients were given HCMV-screened blood products, filtered products were not used on any patient in this cohort. Nevertheless, 15 seronegative patients experienced a primary infection 11 of whom subsequently became seropositive for HCMV. This phenomenon could be explained by insensitive antibody screening assays, or infection posttransplant may have been acquired from close relatives. Interestingly, CMV-specific RNA transcripts have been reported in up to 40% of CMV-seronegative, healthy blood donors, 35 suggesting either an abortive infection or insensitive antibody assays. The observation that the R+D+ patient group had a lower incidence of HCMV disease and lower viral loads than the R+D− group could be explained by adoptive transfer of immunity from the donor resulting in reduced viral replication. 33 Such adoptive transfer of immunity has been demonstrated for tetanus toxoid and hepatitis B vaccines in the bone marrow transplant population. 36 Since both recipient seropositivity, aGVHD and elevated viral load were associated with HCMV disease we used multivariate logistic regression analysis to determine the relative contribution of each of these parameters in the 49 PCR-positive patients. These analyses revealed that viral load was the major factor associated with disease and that the statistical significance of recipient serostatus and aGVHD were abolished (P = 0.93 and 0.11, respectively) after controlling for the effect of viral load.
In the current study there was no difference in virus load or disease between the patients who received marrow from relatives or unrelated donors. Similar data on HCMV disease incidence has recently been reported in children with leukaemia by Hongeng et al. 37 This may be due to improved HLA matching, prevention of GVHD and the effect of antiviral prophylaxis with ACV. Prophylaxis and pre-emptive therapy are now used widely in the management of the bone marrow transplant recipient. [12] [13] [14] [15] [16] [17] In our study all allograft recipients received acyclovir prophylaxis, but the patients were not routinely given pre-emptive ganciclovir therapy. The observation that viral load was significantly higher in patients treated with GCV can be explained by the fact that the majority of patients were given GCV therapy based on clinical assessment of symptoms. Pre-emptive therapy based on PCR positivity was not introduced until the latter part of the study period, but is now routinely applied at our centre. Consequently, we suggest that the patient cohort reported here has allowed aspects of the natural history of HCMV in BMT recipients to be elucidated. Patients with symptoms of HCMV infection were more likely to have been PCR positive for some time prior to the development of symptoms, and as shown in Figure 3 , peak virus load was correspondingly higher in patients with a high frequency of PCR-positive blood samples. We have recently shown that intravenous GCV is very effective at reducing viral load in a patient with TA-GVHD, 38 and we conclude that routine surveillance of BMT patients by blood PCR, together with early initiation of GCV therapy would allow a substantial reduction in overall viral load. Consistent with this rationale, Einsele et al 12 have shown that the use of PCR-guided pre-emptive therapy reduced both the duration of therapy and the incidence of CMV disease in patients treated early with GCV. Immune reconstitution of CMV-specific CD8 CTLs and CD4 T helper cells have been shown to be important for the control of early (Ͻ100 days post-transplant) infection in the bone marrow recipient. 24, 39 Patients receiving GCV therapy for early viraemia have a decreased proliferative response to CMV because of the myeloid toxicity associated with the drug. 40 Thus, reducing the patient's overall exposure to GCV should facilitate a more rapid reconstitution of the immune system.
In order to investigate whether critical viral load thresholds exist above which disease is highly likely, we used the multivariate logistic regression model to compute a disease probability viral load curve. The shape of this curve showed that at viral loads below 3.5 log 10 ge/ml blood the disease probability was less than 10% whereas between 3.5 and 4.5 log 10 ge/ml the probability of disease rose six-fold and reached 80% at 5.0 log 10 ge/ml blood. In similar studies we have identified threshold viral load levels for disease in the blood of liver transplant recipients, 20 and in the urine of renal transplant patients. 21 In conclusion, the data in this study demonstrate the central role of viral load in the pathogenesis of HCMV in the bone marrow transplant recipient and provide the mechanism by which previously identified risk factors are associated with disease. These data also provide a rational approach to reducing viral loads below critical levels through antiviral chemotherapeutic targeting of patients most at risk of symptomatic infection, as well as monitoring the success of such interventions.
